{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T22:28:46Z","timestamp":1763504926468,"version":"3.45.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012351","name":"Mitsubishi Tanabe Pharma Corporation","doi-asserted-by":"publisher","award":["04\\u2013078-0080"],"award-info":[{"award-number":["04\\u2013078-0080"]}],"id":[{"id":"10.13039\/501100012351","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.cyto.2025.157059","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T03:35:37Z","timestamp":1760672137000},"page":"157059","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Serum interleukin-1 receptor antagonist levels are a useful marker of disease activity and risk of relapse in large vessel vasculitis."],"prefix":"10.1016","volume":"196","author":[{"given":"Koji","family":"Suzuki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sho","family":"Ishigaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuhiro","family":"Akiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiko","family":"Yoshimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Waleed","family":"Alshehri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanako","family":"Shimanuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Takei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriyasu","family":"Seki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideto","family":"Tsujimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Chiba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cyto.2025.157059_bb0005","article-title":"Large-vessel vasculitis (Primer)","volume":"7","author":"Pugh","year":"2021","journal-title":"Nature Reviews: Disease Primers; London"},{"key":"10.1016\/j.cyto.2025.157059_bb0010","article-title":"Innate and adaptive immunity in Giant cell arteritis","volume":"11","author":"Akiyama","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cyto.2025.157059_bb0015","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1613849","article-title":"Trial of tocilizumab in Giant-cell arteritis","volume":"377","author":"Stone","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cyto.2025.157059_bb0020","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1136\/annrheumdis-2017-211878","article-title":"Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study)","volume":"77","author":"Nakaoka","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.cyto.2025.157059_bb0025","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1136\/annrheumdis-2012-201836","article-title":"Increased IL-17A expression in temporal artery lesions is a predictor of sustained response to glucocorticoid treatment in patients with giant-cell arteritis","volume":"72","author":"Esp\u00edgol-Frigol\u00e9","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.cyto.2025.157059_bb0030","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1161\/CIRCULATIONAHA.109.872903","article-title":"Th17 and Th1 T-cell responses in giant cell arteritis","volume":"121","author":"Deng","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.cyto.2025.157059_bb0035","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1307","article-title":"Interleukin-1 pathway in active large vessel vasculitis patients with a poor prognosis: a longitudinal transcriptome analysis","volume":"10","author":"Matsumoto","year":"2021","journal-title":"Clin. Transl. Immunology"},{"key":"10.1016\/j.cyto.2025.157059_bb0040","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/art.1780400105","article-title":"Disease patterns and tissue cytokine profiles in giant cell arteritis","volume":"40","author":"Weyand","year":"1997","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.cyto.2025.157059_bb0045","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-004600","article-title":"Genes deregulated in giant cell arteritis by Nanostring nCounter gene expression profiling in temporal artery biopsies","volume":"10","author":"Ferrigno","year":"2024","journal-title":"RMD Open"},{"key":"10.1016\/j.cyto.2025.157059_bb0050","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/nrrheum.2016.166","article-title":"Interleukin-1 function and role in rheumatic disease","volume":"12","author":"Schett","year":"2016","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.cyto.2025.157059_bb0055","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1161\/CIRCULATIONAHA.105.564658","article-title":"Involvement of tumor necrosis factor-alpha in the development of T cell-dependent aortitis in interleukin-1 receptor antagonist-deficient mice","volume":"112","author":"Matsuki","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.cyto.2025.157059_bb0060","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1002\/art.1780330810","article-title":"The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis","volume":"33","author":"Hunder","year":"1990","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.cyto.2025.157059_bb0065","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1002\/art.1780330811","article-title":"The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis","volume":"33","author":"Arend","year":"1990","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.cyto.2025.157059_bb0070","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/annrheumdis-2019-215672","article-title":"2018 update of the EULAR recommendations for the management of large vessel vasculitis","volume":"79","author":"Hellmich","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.cyto.2025.157059_bb0075","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1093\/rheumatology\/ket128","article-title":"Development and initial validation of the Indian Takayasu clinical activity score (ITAS2010)","volume":"52","author":"Misra","year":"2013","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.cyto.2025.157059_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2022.105494","article-title":"Epidemiology and predictors of relapse in giant cell arteritis: a systematic review and meta-analysis","volume":"90","author":"Moreel","year":"2023","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.cyto.2025.157059_bb0085","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1359-6101(02)00020-5","article-title":"The balance between IL-1 and IL-1Ra in disease","volume":"13","author":"Arend","year":"2002","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.cyto.2025.157059_bb0090","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2022.1036233","article-title":"Transcriptome profiling of abdominal aortic tissues reveals alterations in mRNAs of Takayasu arteritis","volume":"13","author":"Yuqing","year":"2022","journal-title":"Front. Genet."},{"key":"10.1016\/j.cyto.2025.157059_bb0095","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1093\/rheumatology\/keh058","article-title":"Tissue production of pro-inflammatory cytokines (IL-1beta, TNFalpha and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis","volume":"43","author":"Hern\u00e1ndez-Rodr\u00edguez","year":"2004","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.cyto.2025.157059_bb0100","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.1093\/rheumatology\/keae072","article-title":"Serum protein profiling reveals distinct patient clusters in giant cell arteritis","volume":"63","author":"Zingg","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.cyto.2025.157059_bb0105","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.859502","article-title":"Pathogenic role of monocytes\/macrophages in large vessel vasculitis","volume":"13","author":"Watanabe","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cyto.2025.157059_bb0110","doi-asserted-by":"crossref","first-page":"17067","DOI":"10.1038\/s41598-019-53633-0","article-title":"IL-25 exacerbates autoimmune aortitis in IL-1 receptor antagonist-deficient mice","volume":"9","author":"Yoshizaki","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cyto.2025.157059_bb0115","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1093\/rheumatology\/37.7.797","article-title":"Circulating levels of IL-1beta, IL-6 and soluble IL-2 receptor in polymyalgia rheumatica and giant cell arteritis and rheumatoid arthritis","volume":"37","author":"Pountain","year":"1998","journal-title":"Br. J. Rheumatol."},{"key":"10.1016\/j.cyto.2025.157059_bb0120","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s10067-018-4240-x","article-title":"Utility of serological biomarkers for giant cell arteritis in a large cohort of treatment-na\u00efve patients","volume":"38","author":"Burja","year":"2019","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.cyto.2025.157059_bb0125","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s00296-022-05186-1","article-title":"Association of immunological parameters with aortic dilatation in giant cell arteritis: a cross-sectional study","volume":"43","author":"Jud","year":"2023","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.cyto.2025.157059_bb0130","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1093\/rheumatology\/keu526","article-title":"Serum markers associated with disease activity in giant cell arteritis and polymyalgia rheumatica","volume":"54","author":"van der Geest","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.cyto.2025.157059_bb0135","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.2147\/JIR.S355881","article-title":"Novel Th17 lymphocyte populations, Th17.1 and PD1+Th17, are increased in Takayasu arteritis, and both Th17 and Th17.1 sub-populations associate with active disease","volume":"15","author":"Singh","year":"2022","journal-title":"J. Inflamm. Res."},{"key":"10.1016\/j.cyto.2025.157059_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinsp.2023.100256","article-title":"Serum cytokines in childhood-Takayasu arteritis: are they biomarkers for indolent disease activity?","volume":"78","author":"Clemente","year":"2023","journal-title":"Clinics (Sao Paulo)"},{"key":"10.1016\/j.cyto.2025.157059_bb0145","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1002\/(SICI)1521-4141(199808)28:08<2598::AID-IMMU2598>3.0.CO;2-K","article-title":"IL-1 receptor antagonist (IL-1Ra) plasma levels are co-ordinately regulated by both IL-1Ra and IL-1beta genes","volume":"28","author":"Hurme","year":"1998","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.cyto.2025.157059_bb0150","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1136\/ard-2024-225630","article-title":"Association between premature vascular smooth muscle cells senescence and vascular inflammation in Takayasu\u2019s arteritis","volume":"83","author":"Fang","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.cyto.2025.157059_bb0155","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1084\/jem.191.2.303","article-title":"Arterial inflammation in mice lacking the interleukin 1 receptor antagonist gene","volume":"191","author":"Nicklin","year":"2000","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.cyto.2025.157059_bb0160","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1161\/CIRCULATIONAHA.104.519132","article-title":"Elastic-vessel arteritis in interleukin-1 receptor antagonist-deficient mice involves effector Th1 cells and requires interleukin-1 receptor","volume":"111","author":"Shepherd","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.cyto.2025.157059_bb0165","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/s41598-018-36825-y","article-title":"Serum levels of fibroblast growth factor-2 distinguish Takayasu arteritis from giant cell arteritis independent of age at diagnosis","volume":"9","author":"Fukui","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cyto.2025.157059_bb0170","doi-asserted-by":"crossref","first-page":"1165758","DOI":"10.3389\/fimmu.2023.1165758","article-title":"Serum proteomics in giant cell arteritis in response to a three-day pulse of glucocorticoid followed by tocilizumab monotherapy (the GUSTO trial)","volume":"14","author":"Christ","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cyto.2025.157059_bb0175","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1136\/ard-2024-225868","article-title":"Plasma proteome profiling in giant cell arteritis","volume":"83","author":"Cunningham","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.cyto.2025.157059_bb0180","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1136\/ard-2023-225270","article-title":"Vascular disease persistence in giant cell arteritis: are stromal cells neglected?","volume":"83","author":"Karabayas","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.cyto.2025.157059_bb0185","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/art.39037","article-title":"Th1 and Th17 cytokines drive inflammation in Takayasu arteritis: Th1 AND Th17 CELLS in Takayasu arteritis","volume":"67","author":"Saadoun","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.cyto.2025.157059_bb0190","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1093\/rheumatology\/keab280","article-title":"Steroid-sparing effect of anakinra in giant-cell arteritis: a case series with clinical, biological and iconographic long-term assessments","volume":"61","author":"Deshayes","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.cyto.2025.157059_bb0195","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jbspin.2013.06.004","article-title":"Interleukin-1 blockade in refractory giant cell arteritis","volume":"81","author":"Ly","year":"2014","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.cyto.2025.157059_bb0200","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s13075-025-03493-z","article-title":"Four months of treatment with anakinra combined with glucocorticoids for giant cell arteritis: a multicenter, randomized, double-blind, placebo-controlled trial","volume":"27","author":"de Boysson","year":"2025","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.cyto.2025.157059_bb0205","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.semarthrit.2020.01.005","article-title":"Drug retention and discontinuation reasons between seven biologics in patients with Takayasu arteritis","volume":"50","author":"Campochiaro","year":"2020","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.cyto.2025.157059_bb0210","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/j.semarthrit.2021.09.010","article-title":"Biologic treatments in Takayasu\u2019s arteritis: a comparative study of tumor necrosis factor inhibitors and tocilizumab","volume":"51","author":"Alibaz-Oner","year":"2021","journal-title":"Semin. Arthritis Rheum."}],"container-title":["Cytokine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466625002066?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466625002066?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T22:26:30Z","timestamp":1763504790000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043466625002066"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":42,"alternative-id":["S1043466625002066"],"URL":"https:\/\/doi.org\/10.1016\/j.cyto.2025.157059","relation":{},"ISSN":["1043-4666"],"issn-type":[{"type":"print","value":"1043-4666"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serum interleukin-1 receptor antagonist levels are a useful marker of disease activity and risk of relapse in large vessel vasculitis.","name":"articletitle","label":"Article Title"},{"value":"Cytokine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cyto.2025.157059","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"157059"}}